FLOT vs CROSS in localized esophageal adenocarcinoma: what is the current best strategy?

Expert Rev Clin Pharmacol. 2025 Jan 2:1-3. doi: 10.1080/17512433.2024.2447779. Online ahead of print.

Authors

Jane E Rogers¹, Michael Leung¹, Jaffer A Ajani²

Affiliations

¹ Pharmacy Clinical Programs, U.T. M.D. Anderson Cancer Center, Houston, TX, USA.
² Department of Gastrointestinal Medical Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX, USA.

PMID: 39737726
DOI: 10.1080/17512433.2024.2447779

No abstract available

Keywords: Chemoradiation; docetaxel; esophageal neoplasms; fluorouracil; oxaliplatin.

Publication types

Editorial